Possible association between genetic variability at the apolipoprotein(a) locus and Alzheimer's disease in apolipoprotein E2 carriers

Neuroscience Letters

Volumn 331, Issue 1, 2002, Pages 60-62

  Compton, Danielle ^a,b   Wavrant DeVriéze, Fabienne ^a,b   Petersen, Ronald C ^c   Tangalos, Eric ^c   Li, Ling ^d   Hardy, John ^a,b,e  

^a MAYO GRADUATE SCHOOL   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c MAYO CLINIC   (United States)

^d University of Alabama at Birmingham   (United States)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; Apolipoprotein(a); Apolipoprotein(a) locus; Cholesterol; Lipoprotein(a); Polymorphisms

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN E2; CARRIER PROTEIN;

ALLELE; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; KRINGLE DOMAIN; MAJOR CLINICAL STUDY; POLYMORPHIC LOCUS; PRIORITY JOURNAL;

ALZHEIMER DISEASE; APOLIPOPROTEIN E2; APOLIPOPROTEINS; APOLIPOPROTEINS E; APOPROTEIN(A); CASE-CONTROL STUDIES; GENOTYPE; HUMANS; KRINGLES; LIPOPROTEIN(A); POINT MUTATION; VARIATION (GENETICS);

EID: 0037020491     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(02)00703-6     Document Type: Article

References (17)

1. Corder E.H., Saunders A.M., Strittmatter W.J., Schechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's Disease in late onset families. Science. 261:1993;921-923.
2. de Knijff P., Kaptein A., Boomsma D., Princen H.M., Frants R.R., Havekes L.M. Apolipoprotein E polymorphism affects plasma levels of lipoprotein(a). Atherosclerosis. 90:1991;169-174.
3. Fassbender K., Simons M., Bergmann C., Stroick M., Lutjohann D., Keller P., Runz H., Kuhl S., Bertsch T., von Bergmann K., Hennerici M., Beyreuther K., Hartmann T. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl. Acad. Sci. USA. 98:2001;5856-5861.
4. Henderson J.N., Crook R., Crook J., Hardy J., Onstead L., Carson-Henderson L., Mayer P., Parker B., Petersen R., Williams B. Apolipoprotein E4 and tau allele frequencies among Choctaw Indians. Neurosci. Lett. 324:2002;77-79.
5. Hobbs H.H., White A.L. Lipoprotein(a): intrigues and insights. Curr. Opin. Lipidol. 10:1999;225-236.
6. Horita K., Eto M., Saito M., Nakata H., Iwashima Y., Ito H., Takahashi M., Kondo A., Morikawa A., Makino I. Effects of apolipoprotein E polymorphism on plasma lipoprotein(a) levels. Artery. 20:1993;324-336.
7. Jick H., Zornberg G.L., Jick S.S., Seshadri S., Drachman D.A. Statins and the risk of dementia. Lancet. 356:2000;1627-1631.
8. McLean J.W., Tomlinson J.E., Kuang W.-J., Eaton D.L., Chen E.Y., Fless G.M., Scanu A.M., Lawn R.M. cDNA sequence of human apolipoprotein (a) is homologous to plasminogen. Nature. 300:1987;132-137.
9. Mooser V., Helbecque N., Mildossy J., Marcovina S., Nicod P., Amouyel P. Interactions between apolipoprotein E and apolipoprotein(a) in patients with late-onset Alzheimer's disease. Ann. Intern. Med. 132:2000;533-537.
10. Myers A., Wavrant De-Vrieze F., Holmans P., Hamshere M., Crook R., Compton D., Marshall H., Meyer D., Shears S., Booth J., Ramic D., Knowles H., Morris J.C., Williams N., Norton N., Abraham R., Kehoe P., Williams H., Rudrasingham V., Rice F., Giles P., Tunstall N., Jones L., Lovestone S., Williams J., Owen M.J., Hardy J., Goate A. Full genome screen for Alzheimer disease: stage II analysis. Am. J. Med. Genet. 114:2002;235-244.
11. Ogorelkova M., Kraft H.G., Ehnholm C., Utermann G. Single nucleotide polymorphisms in exons of the apo(a) kringles IV types 6 to 10 domain affect Lp(a) plasma concentrations and have different patterns in Africans and Caucasians. Hum. Mol. Genet. 10:2001;815-824.
12. Pati U., Pati N. Lipoprotein(a), atherosclerosis, and apolipoprotein(a) gene polymorphism. Mol. Genet. Metab. 71:2000;87-92.
13. Refolo L.M., Pappolla M.A., LaFrancois J., Malester B., Schmidt S.D., Thomas-Bryant T., Tint G.S., Wang R., Mercken M., Petanceska S.S., Duff K.E. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 8:2001;890-899.
14. Ritter M.M., Gewitsch J., Richter W.O., Geiss H.C., Wildner M.W., Schwandt P. Apolipoprotein E polymorphism has no independent effect on plasma levels of lipoprotein(a). Atherosclerosis. 131:1997;243-248.
15. Sparks D.L., Scheff S.W., Hunsaker J.C. 3rd, Liu H., Landers T., Gross D.R. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp. Neurol. 126:1994;88-94.
16. Wahrle S., Das P., Nyborg A.C., McLendon C., Shoji M., Kawarabayashi T., Younkin L.H., Younkin S.G., Golde T.E. Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol. Dis. 9:2002;11-23.
17. Wolozin B., Kellman W., Ruosseau P., Celesia G.G., Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57:2000;1439-1443.